3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
44
Glioma
16
Melanoma
11
Central Nervous System Neoplasms
11
Astrocytoma
11
Brain Neoplasms
10
Oligodendroglioma
7
Gliosarcoma
5
Small Cell Lung Carcinoma
4
Recurrence
3
Lymphoma
3
Leiomyosarcoma
3
Sarcoma
2
Neoplasms, Neuroepithelial
2
Neoplasms
2
Neoplasm Metastasis
2
Ependymoma
2
Diffuse Intrinsic Pontine Glioma
2
Breast Neoplasms
2
Uveal Melanoma
1
Seizures
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma, Endometrial Stromal
1
Sarcoma, Alveolar Soft Part
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Extensive Stage Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Pituitary Neoplasms
1
Interventions
pomalidomide
1
pembrolizumab
1
Temozolomide
1
Tamsulosin
1
Sodium Selenite
1
Saline Solution
1
Radiomics
1
Lidocaine
1
Hepatectomy
1
Epirubicin
1
Dexamethasone
1
Cyclophosphamide
1
Bevacizumab
1
10-propargyl-10-deazaaminopterin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Disease Progression
×
Temozolomide
×
Clear all
NCT02761070
2023-03-08
RE-GEND
Kyorin University
Phase 3
Unknown
146 enrolled